Tandem Diabetes Care (TNDM) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Tandem Diabetes Care (TNDM) over the last 13 years, with Q3 2025 value amounting to 9.17%.
- Tandem Diabetes Care's EBIT Margin rose 15200.0% to 9.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.48%, marking a year-over-year decrease of 38400.0%. This contributed to the annual value of 10.54% for FY2024, which is 206500.0% up from last year.
- Per Tandem Diabetes Care's latest filing, its EBIT Margin stood at 9.17% for Q3 2025, which was up 15200.0% from 21.53% recorded in Q2 2025.
- Tandem Diabetes Care's EBIT Margin's 5-year high stood at 6.07% during Q4 2021, with a 5-year trough of 75.46% in Q1 2023.
- In the last 5 years, Tandem Diabetes Care's EBIT Margin had a median value of 10.7% in 2024 and averaged 15.46%.
- In the last 5 years, Tandem Diabetes Care's EBIT Margin plummeted by -667400bps in 2023 and then surged by 537200bps in 2024.
- Quarter analysis of 5 years shows Tandem Diabetes Care's EBIT Margin stood at 6.07% in 2021, then tumbled by -233bps to 8.06% in 2022, then crashed by -121bps to 17.82% in 2023, then surged by 99bps to 0.21% in 2024, then tumbled by -4362bps to 9.17% in 2025.
- Its EBIT Margin stands at 9.17% for Q3 2025, versus 21.53% for Q2 2025 and 51.56% for Q1 2025.